Hematología y Hemoterapia

Resultados: 392
Tipo Título / Nombre Autor(es) Año
Midostaurin plus intensive chemotherapy in FLT3 mutated AML De la Fuente A, Diaz Beya M, Beneit P..., Bergua Burgues J 2022
Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the spanish Pethema registry Bernal T, Rad G, Laiglesia A de, Benavente C..., Bergua Burgues J 2022
Pharmacokinetics and pharmacodynamics in first-mind: a phase IB, open-label, randomized study of tafasitamab+ + lenalidomide + R-Chop in patients with newly diagnosed diffuse large B-cell lymphoma Belada D, Kopeckova K, Bergua Burgues J, Stevens D..., Dreyling M 2022
Preliminary results of VEN-A-QUI Study: a phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low- dose cytarabine with venetoclax and quizartinib in newly diagnosed Bergua Burgues JM, Rodríguez Veiga R, Cano I..., Casas Avilés I 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M..., Bergua J, et al 2022
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J..., Bergua JM, et al 2022
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A..., Bergua J, et al 2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma Encinas C, Hernández-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ..., Cabrera C, et al 2022
Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia Martínez López J, Montesinos P, López Muñoz N, Ayala R, Martínez Sánchez P..., Bergua Burgues JM, et al 2022
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M..., Bergua-Burgués JM, et al 2022